Zejula Approval History
FDA Approved: Yes (First approved March 27, 2017)
Brand name: Zejula
Generic name: niraparib
Dosage form: Capsules
Company: Tesaro Inc.
Treatment for: Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
Zejula (niraparib) is an oral, poly ADP-ribose polymerase (PARP) inhibitor for the maintenance treatment of patients with recurrent platinum-sensitive ovarian, fallopian tube, or primary peritoneal cancer.
Development History and FDA Approval Process for Zejula
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.